MBG453
Total Payments
$1.3M
Transactions
28
Doctors
5
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $172,029 | 14 | 4 |
| 2019 | $102,828 | 7 | 2 |
| 2018 | $397,474 | 4 | 0 |
| 2017 | $650,181 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 28 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I THROUGH IB AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $1.3M | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $30,868 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III MULTI-CENTER STUDY OF AZACITIDINE WITH OR WITHOUT MBG453 FOR THE TREATMENT OF PATIENTS WITH INTERMEDIATE, HIGH OR VERY HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) AS PER IPSS-R, OR CHRONIC MYELOMONOCYT | Novartis Pharmaceuticals Corporation | $15,580 | 0 |
| A PHASE I THROUGH IB AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES | NOVARTIS PHARMACEUTICALS CORPORATION | $4,516 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,293 | 2 |
Top Doctors Receiving Payments for MBG453
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $1.3M | 16 |
| , M.D | Internal Medicine | New York, NY | $9,533 | 8 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $7,500 | 1 |
| , M.D | Hematology & Oncology | Boston, MA | $7,500 | 1 |
| , M.D | Hematology | Cincinnati, OH | $7,500 | 1 |
| , M.D | Medical Oncology | San Antonio, TX | $127.33 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 5
- Transactions 28
About MBG453
MBG453 is a drug associated with $1.3M in payments to 5 healthcare providers, recorded across 28 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $172,029 was paid across 14 transactions to 4 doctors.
The most common payment nature for MBG453 is "Unspecified" ($1.3M, 100.0% of total).
MBG453 is associated with 5 research studies, including "A PHASE I THROUGH IB AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES" ($1.3M).